Related Experiment Videos
Isolated extremity perfusion with DTIC. An experimental and clinical study
Anticancer Research
|March 1, 1983
Summary
Dacarbazine (DTIC) isolated extremity perfusion showed good tolerance in dogs. In humans, this chemotherapy method achieved significant tumor regression for advanced extremity cancers.
Area of Science:
- Oncology
- Pharmacology
- Surgical Oncology
Background:
- Isolated limb perfusion (ILP) is a regional chemotherapy technique.
- Dacarbazine (DTIC) is an alkylating agent used in cancer treatment.
Purpose of the Study:
- To evaluate the safety and efficacy of Dacarbazine (DTIC) in isolated perfusion of extremities.
- To assess DTIC's tolerability and potential for tumor regression in canine and human models.
Main Methods:
- Canine models underwent extremity perfusion with DTIC at doses up to 100 mg/kg.
- Human patients with advanced extremity sarcomas or melanomas received DTIC perfusion at 75-133 mg/kg at 40°C for 60 minutes.
Main Results:
- DTIC perfusion was well-tolerated in dogs, with no observed vascular damage.
- Electron microscopy in dogs showed decreased muscle glycogen post-perfusion.
- Human patients experienced tumor regression of at least 30%.
Conclusions:
- Isolated limb perfusion with Dacarbazine (DTIC) is a feasible and potentially effective treatment for advanced extremity cancers.
- DTIC demonstrates good local tolerance and significant anti-tumor activity in this regional delivery method.